Elixiron Immunotherapeutics Closes $27 Million Series A-1 Financing Round to Progress Alzheimer’s Disease and Vitiligo Clinical-Stage Assets

At Elixiron Immunotherapeutics, we are on a mission to develop next-generation therapeutics for cancer, neurological diseases and inflammatory disorders by tapping into what clinical findings can teach us for reverse-translational medicine approaches, together with our drug discovery engine and expertise in antibody and bifunctional biologics development. Today, we are honored to be able to announce the closing of our Series A-1 extension financing round from both new and existing investors, bringing the total Series A-1 raise to $27 million. Read the press release here.